Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2712-2718

  Rajotte, D ^a   Tremblay, S ^a   Pelletier, A ^a   Salois, P ^a   Bourgon, L ^a,c   Coulombe, R ^a   Mason, S ^a,b   Lamorte, L ^a   Sturino, C F ^a,d   Bethell, R ^a,e  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b BRISTOL MYERS SQUIBB   (United States)

^c Jubilant DraxImage   (Canada)

^d VERTEX PHARMACEUTICALS   (United States)

^e MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DNA DIRECTED DNA POLYMERASE GAMMA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BENZOFURANS; DRUG RESISTANCE, VIRAL; HIGH-THROUGHPUT SCREENING ASSAYS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84877847712     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00113-13     Document Type: Article

References (32)

1. Basavapathruni A, Anderson KS. 2007. Reverse transcription of the HIV-1 pandemic. FASEB J. 21:3795-3808.
2. Tarrago-Litvak L, Andréola ML, Nevinsky GA, Sarih-Cottin L, Litvak S. 1994. The reverse transcriptase of HIV-1: From enzymology to therapeutic intervention. FASEB J. 8:497-503.
3. Herschhorn A, Hizi A. 2010. Retroviral reverse transcriptases Cell. Mol. Life Sci. 67:2717-2747.
4. De Clercq. 2010. Antiretroviral drugs. Curr. Opin. Pharmacol. 10:507-515.
5. Wainberg MA, Zaharatos GJ, Brenner BG. 2011. Development of antiretroviral drug resistance. N. Engl. J. Med. 365:637-646.
6. Koczor CA, Lewis W. 2010. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin. Drug Metab. Toxicol. 6:1493-1504.
7. Jochmans D, Deval J, Kesteleyn B, Van Marck H, Bettens E, De Baere I, Dehertogh P, Ivens Van Ginderen TM, Van Schoubroeck B, Ehteshami M, Wigerinck P, Götte M, Hertogs K. 2006. Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action. J. Virol. 80:12283-12292.
8. Zhang Z, Walker M, Xu W, Hoon Shim J, Girardet JL, Hamatake RK, Hong Z. 2006. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 50:2772-2781.
9. Ehteshami M, Scarth BJ, Tchesnokov EP, Dash C, Le Grice SFJ, Hallenberger S, Jochmans D, Götte M. 2008. Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against "nucleotidecompeting reverse transcriptase inhibitors." J. Biol. Chem. 283:29904-29911.
10. Jegede O, Khodyakova A, Chernov M, Weber J, Menéndez-Arias L, Gudkov A, Quiñones-Mateu ME. 2011. Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based highthroughput screening system. Antiviral Res. 91:94-98.
11. Jochmans D, Van Schoubroeck B, Ivens T, Dehertogh P, Kesteleyn B, Hertogs K. 2005. ATP enhances the inhibitory effect of NcRTIs (nucleotide competing RT inhibitors). Antivir. Ther. 10(Suppl 1):A83.
12. Jochmans D. 2008. Novel HIV-1 reverse transcriptase inhibitors. Virus Res. 134:171-185.
13. Götte M, Rausch JW, Marchand B, Sarafianos S, Le Grice SFJ. 2010. Reverse transcriptase in motion: Conformational dynamics of enzymesubstrate interactions. Biochim. Biophys. Acta 1804:1202-1212.
14. Miller MD. 2004. K65R, TAMs and tenofovir. AIDS Rev. 6:22-33.
15. Di Re M, Sembongi H, He J, Reyes A, Yasukawa T, Martinsson P, Bailey LJ, Goffart S, Boyd-Kirkup JD, Wong TS, Fersht AR, Spelbrink JN, Holt IJ. 2009. The accessory subunit of mitochondrial DNA polymerase-determines the DNA content of mitochondrial nucleoids in human cultured cells. Nucleic Acids Res. 37:5701-5713.
16. Lee YS, Dexter Kennedy W, Whitney Yin Y. 2009. Structural insight into processive human mitochondrialDNAsynthesis and disease-related polymerase mutations. Cell 139:312-324.
17. Parker WB, White EL, Shaddix SC, Ross LJ, Buckheit RW, Germany JM, Secrist JA III, Vincell R, Shannon WM. 1991. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases-,-and-by the 5=-triphosphates of carbovir, 3=-Azido-3=- deoxythymidine,2=,3=-dideoxyguanosine, and 3=-deoxythymidine. J. Biol. Chem. 266:1754-1762.
18. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
19. Lemke CT, Titolo S, von Schwedler U, Goudreau N, Mercier JF, Wardrop E, Faucher AM, Coulombe R, Banik SS, Fader L, Gagnon A, Kawai SH, Rancourt J, Tremblay M, Yoakim C, Simoneau B, Archambault J, Sundquist WI, Mason SW. 2012. Distinct effects of two HIV-1 capsid assembly inhibitor famillies that bind the same site within the Nterminal domain of the viral CA protein. J. Virol. 86:6643-6655.
20. Lansdon EB, Samuel D, Lagpacan L, Brendza KM, White KL, Hung M, Liu X, Boojamra CG, Mackman RL, Cihlar T, Ray AS, McGrath ME, Swaminathan S. 2010. Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. J. Mol. Biol. 397:967-978.
21. Maga G, Radi M, Zanoli S, Manetti F, Cancia R, Hübscher U, Spadari S, Falciani C, Terrazas M, Vilarrasa J, Botta M. 2007. Discovery of non-nucleoside inhibitors of HIV-1 reverse transcriptase competing with the nucleotide substrate. Angew. Chem. 46:1810-1813.
22. Maga G, Radi M, Gerard MA, Botta M, Ennifar E. 2010. HIV-1 RT inhibitors with a novel mechanism of action: NNRTIs that compete with the nucleotide substrate. Viruses 2:880-899.
23. Freisz S, Bec G, Radi M, Wolff P, Crespan E, Angeli L, Dumas P, Maga G, Botta M, Ennifar E. 2010. Crystal structure of HIV-1 reverse transcriptase bound to a non-nucleoside inhibitor with a novel mechanism of action. Angew. Chem. 49:1-5.
24. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. 2001. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75:4832-4842.
25. Ehteshami M, Nijhuis M, Ablenas C, Bernatchez J, McCormick S, De Jong TMC, Jochmans DD, Götte M. 2012. Plasticity of the ATP binding site of HIV-1 RT promotes binding of both INDOPY-1 and its ATP enhancer to the post-translocated complex. Antiviral Ther. 17(Suppl 1):A54.
26. Das K, Sarafianos SG, Arthur Clark DAD, Boyer PL, Hughes SH, Arnold E. 2007. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside Inhibitor HBY 097. J. Mol. Biol. 365:77-89.
27. Boucher S, Recordon-Pinson P, Ragnaud JM, Dupon M, Fleury H, Masquelier B. 2006. HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation. HIV Med. 7:294-298.
28. Coutsinos D, Invernizzi CF, Moisi D, Maureen Oliveira M, Martinez-Cajas JL, Bluma G. Brenner BG, Wainberg MA. 2011. A templatedependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One 6:e20208. doi:10.1371/journal.pone.0020208.
29. Das K, Rajiv Bandwar PRP, White KL, Feng JY, Sarafianos SG, Tuske S, Tu X, Clark AD, Jr, Boyer PL, Hou X, Gaffney BL, Jones RA, Miller MD, Hughes SH, Arnold E. 2009. Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J. Biol. Chem. 284:35092-35100.
30. Sharma B, Kaushik N, Singh K, Kumar S, Pandey VN. 2002. Substitution of conserved hydrophobic residues in motifs B and C of HIV-1 RT alters the geometry of its catalytic pocket. Biochemistry 41:15685-15697.
31. Petruska J, Sowers LC, Goodman MF. 1986. Comparison of nucleotide interactions in water, proteins, and vacuum: Model for DNA polymerase fidelity. Proc. Natl. Acad. Sci. U. S. A. 83:1559-1562.
32. Sturino CF, Bousquet Y, James CA, DeRoy P, Duplessis M, Edwards PJ, Halmos T, Minville J, Morency L, Morin S, Thavonekham B, Tremblay M, Duan J, Ribadeneira M, Garneau M, Pelletier A, Tremblay S, Lamorte L, Bethell R, Cordingley MG, Rajotte D, Simoneau B. Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors; in vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors. Bioorg. Med. Chem. Lett., in press.